The Certara team helped develop a quantitative framework that bridges the disciplines of pharmacology, epidemiology, and health economics to support meaningful dialogue between industry, regulators, and payers.
In this webinar, we will discussed how we combined clinical and pre-clinical approaches to develop a PBPK model to predict the exposure of darunavir, a protease inhibitor commonly used to treat pregnant HIV+ patients. Moreover, we elaborated on the study design, data collection, and analyses that were used to investigate the clinical pharmacokinetics of antiretroviral agents during pregnancy.
Scientists from Certara’s Strategic Consulting division helped Alios Biopharma develop a novel drug to treat respiratory syncytial virus (RSV) infection in infants.
PRINCETON, NJ – Sept. 6, 2017 – Certara today announced that its comprehensive influenza viral kinetic modeling review has just been published in Current Pharmacology Reports. As the number of drug-resistant influenza strains grows, researchers are searching for better ways to develop safer, more effective anti-viral drugs. Viral kinetic modeling, in combination with PK/PD modeling, is proving to be a fruitful resource.
Watch this webinar with C-Path’s Dr. Klaus Romero to learn how they integrated these components into the latest version of the Simcyp Simulator to establish a robust resource that will help development teams and regulators evaluate the safety and efficacy of novel anti-TB drug regimens.
The Quantify HBV Database is developed to document clinical safety and efficacy information on different nucleosides (eg, entecavir, lamivudine, tenofovir disoproxil fumarate, telbivudine, adefovir and combination) focusing on 3 different endpoints: HBV DNA time course, HBsAG time course, and HBeAG seroconversion that are available in the public domain.
